Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## 華領醫藥

(Incorporated in the Cayman Islands with limited liability) (stock code: 2552)

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The board (the "Board") of directors (the "Directors") of Hua Medicine (the "Company") announces that on August 30, 2021, the Company granted share options (the "Share Options") to an employee of the Company (the "Grantee") pursuant to the Company's share option scheme which was conditionally approved and adopted on August 26, 2018 and effective beginning September 14, 2018 (the "Share Option Scheme"), subject to acceptance by the Grantee. The Share Options entitle the Grantee to subscribe for a total of 200,000 new shares with a nominal value of US\$0.001 each (the "Shares") in the share capital of the Company.

Details of the Share Options granted are as follows:

Date of Grant: August 30, 2021

Exercise price of HK\$4.560 per Share

Share Options granted:

Closing price of the Shares on

the date of grant:

HK\$4.560 per Share

Number of Share Options granted: 200,000 (each Share Option shall entitle the holder thereof

to subscribe for one (1) Share)

Validity period of the Share Options: Ten (10) years from the date of grant

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, the Grantee is not a Director, chief executive or substantial shareholder of the Company, or an associate (as defined in the Listing Rules) of any of them.

By Order of the Board **Dr. Li Chen**Chief Executive Officer and

Executive Director

Hong Kong, August 30, 2021

As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.